General Catalyst-backed Commure is buying another General Catalyst-backed startup that sends follow-up texts to patients. Commure, which was valued at over … Sign up to
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Syncromune, a biotech startup working on combination immunotherapies, has put together a $100 million Series A, the company told Endpoints News. The round was led
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
The company’s stock has dropped by 15% after the Phase II trial data was announced. Image credit: Shutterstock / pathdoc Vertex Pharmaceuticals’s non-opioid-based pain therapy
The FDA approved a once-daily oral combination of vanzacaftor/tezacaftor/deutivacaftor (Alyftrek) for cystic fibrosis (CF) in adults and children 6 years and up, drugmaker Vertex Pharmaceuticals
The FDA approved tirzepatide (Zepbound) for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity, the agency announced late Friday. Used along with diet and
The FDA on Friday approved acellular tissue engineered vessel (Symvess), an off-the-shelf product for treating vascular trauma in the extremities of adults. The one-time, single-use